Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 2, 2007, Pages 347-355

  Ganswindt, Ute ^a   Paulsen, Frank ^a   Corvin, Stefan ^a   Hundt, Ilse ^a   Alber, Markus ^a   Frey, Bettina ^a   Stenzl, Arnulf ^a   Bares, Roland ^a   Bamberg, Michael ^a   Belka, Claus ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Coverage; High risk prostate cancer; Intensity modulated radiation therapy; Pelvic lymph node; Sentinel node

Indexed keywords

ALGORITHMS; COMPUTER SIMULATION; COMPUTERIZED TOMOGRAPHY; DISEASE CONTROL; DOSIMETRY; HEALTH RISKS; MONTE CARLO METHODS; ONCOLOGY; RADIOTHERAPY;

HIGH RISK PROSTATE CANCERS; INTENSITY MODULATED RADIATION THERAPY; PELVIC LYMPH NODES; SENTINEL NODES;

TUMORS;

ALGORITHM; ARTICLE; CLINICAL ARTICLE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LYMPHATIC DRAINAGE; MALE; MATHEMATICAL COMPUTING; MONTE CARLO METHOD; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; RISK ASSESSMENT; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; TREATMENT PLANNING;

ALGORITHMS; COLON, SIGMOID; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MONTE CARLO METHOD; NEOPLASM STAGING; PELVIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; URINARY BLADDER;

EID: 33846185896     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.08.082     Document Type: Article

References (44)

1. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
2. Lawton C.A., De Silvio M.M.R., et al. An update of the phase III trial comparing whole-pelvic to prostate only radiotherapy and neoadjuvant total androgen suppression: Updated analysis of RTOG 94-13. [Abstract]. Int J Radiat Oncol Biol Phys 63 (2005) S19
3. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360 (2002) 103-106
4. Seaward S.A., Weinberg V., Lewis P., et al. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 42 (1998) 1055-1062
5. Lawton C.A., Winter K., Murray K., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49 (2001) 937-946
6. Pilepich M.V., Winter K., John M.J., et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
7. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
8. Horwitz E.M., Winter K., Hanks G.E., et al. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 49 (2001) 947-956
9. Pommier P., Perol D., Lagrange J., et al. Does pelvis and prostate radiation therapy compared to prostate radiation therapy alone improve survival in patients with non metastatic prostate carcinoma?. Preliminary results of the prospective randomized GETUG 01 trial. [Abstract]. Int J Radiat Oncol Biol Phys 63 (2005) S19
10. Wawroschek F., Vogt H., Wengenmair H., et al. Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int 70 (2003) 303-310
11. Wawroschek F., Wagner T., Hamm M., et al. The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 43 (2003) 132-136 discussion 137
12. Weckermann D., Hamm M., Dorn R., et al. Sentinel lymph node dissection in prostate cancer: Experience after more than 800 interventions. Urologe A 45 (2006) 723-727
13. Weckermann D., Wawroschek F., and Harzmann R. Is there a need for pelvic lymph node dissection in low risk prostate cancer patients prior to definitive local therapy?. Eur Urol 47 (2005) 45-50 discussion 50-41
14. Heidenreich A., Varga Z., and Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: High incidence of lymph node metastasis. J Urol 167 (2002) 1681-1686
15. Golimbu M., Morales P., Al-Askari S., et al. Extended pelvic lymphadenectomy for prostatic cancer. J Urol 121 (1979) 617-620
16. Speight J.L., and Roach III M. Radiotherapy in the management of clinically localized prostate cancer: Evolving standards, consensus, controversies and new directions. J Clin Oncol 23 (2005) 8176-8185
17. Freeman J.A., Esrig D., Grossfeld G.D., et al. Incidence of occult lymph node metastases in pathological stage C (pT3N0) prostate cancer. J Urol 154 (1995) 474-478
18. Edelstein R.A., Zietman A.L., de las Morenas A., et al. Implications of prostate micrometastases in pelvic lymph nodes: An archival tissue study. Urology 47 (1996) 370-375
19. Ferrari A.C., Stone N.N., Eyler J.N., et al. Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer. J Natl Cancer Inst 89 (1997) 1498-1504
20. Ganswindt U., Paulsen F., Corvin S., et al. Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition. BMC Cancer 5 (2005) 91
21. Roach III M., Marquez C., Yuo H.S., et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28 (1994) 33-37
22. Martinez-Monge R., Fernandes P.S., Gupta N., et al. Cross-sectional nodal atlas: A tool for the definition of clinical target volumes in three-dimensional radiation therapy planning. Radiology 211 (1999) 815-828
23. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 (2001) 843-848
24. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. J Am Med Assoc 277 (1997) 1445-1451
25. Alber M., and Nusslin F. Optimization of intensity modulated radiotherapy under constraints for static and dynamic MLC delivery. Phys Med Biol 46 (2001) 3229-3239
26. Adli M., Mayr N.A., Kaiser H.S., et al. Does prone positioning reduce small bowel dose in pelvic radiation with intensity-modulated radiotherapy for gynecologic cancer?. Int J Radiat Oncol Biol Phys 57 (2003) 230-238
27. Bagshaw M.A., Cox R.S., and Ray G.R. Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr (1988) 47-60
28. McGowan D.G. The value of extended field radiation therapy in carcinoma of the prostate. Int J Radiat Oncol Biol Phys 7 (1981) 1333-1339
29. Perez C.A., Michalski J., Brown K.C., et al. Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 36 (1996) 573-584
30. Ploysongsang S., Aron B.S., Shehata W.M., et al. Comparison of whole pelvis versus small-field radiation therapy for carcinoma of prostate. Urology 27 (1986) 10-16
31. Rangala N., Cox J.D., Byhardt R.W., et al. Local control and survival after external irradiation for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 8 (1982) 1909-1914
32. Hauschild A., Rosien F., and Lischner S. Surgical standards in the primary care of melanoma patients. Onkologie 26 (2003) 218-222
33. Veronesi U., Paganelli G., Viale G., et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349 (2003) 546-553
34. Balkissoon J., Rasgon B.M., and Schweitzer L. Lymphatic mapping for staging of head and neck cancer. Semin Oncol 31 (2004) 382-393
35. Corvin S., Eichhorn K., Wurm T., et al. Radioisotope guided laparoscopic pelvic lymph node dissection-a novel technique for prostate cancer staging. Eur Urol 3 Suppl (2004) 140
36. Corvin S., Schilling D., Eichhorn K., et al. Laparoscopic sentinel lymph node dissection-a novel technique for the staging of prostate cancer. Eur Urol 49 (2006) 280-285
37. Nutting C.M., Convery D.J., Cosgrove V.P., et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 48 (2000) 649-656
38. Adams E.J., Convery D.J., Cosgrove V.P., et al. Clinical implementation of dynamic and step-and-shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvement. Radiother Oncol 70 (2004) 1-10
39. Mundt A.J., Lujan A.E., Rotmensch J., et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 52 (2002) 1330-1337
40. Luxton G., Hancock S.L., and Boyer A.L. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 59 (2004) 267-284
41. Wang-Chesebro A., Coleman J., Xia P., et al. IMRT improves pelvic lymph node (PLN) coverage and dose to critical structures compared with standard four field (4F) whole pelvis (WP) radiation therapy (RT) in prostate cancer. [Abstract]. Int J Radiat Oncol Biol Phys 63 (2005) S194
42. Ashman J.B., Zelefsky M.J., Hunt M.S., et al. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 765-771
43. Sanguineti G., Cavey M.L., Endres E.J., et al. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?. Int J Radiat Oncol Biol Phys 64 (2006) 151-160
44. Cavey M.L., Bayouth J.E., Colman M., et al. IMRT to escalate the dose to the prostate while treating the pelvic nodes. Strahlenther Onkol 181 (2005) 431-441